14 November 2016
Today, the Danish Supreme Court will deliver its judgment in the case that arose from NeuroSearch’s announcement in February 2010 presenting top-line results from a Phase III clinical study of the drug candidate Huntexil®. NeuroSearch has previously received two lower instance judgments for violation the ban on market manipulation, ordering NeuroSearch to pay a fine of DKK 5 million. We refer to our previously issued company announcements.
On the occasion of the delivery of judgment, NeuroSearch has requested NASDAQ Copenhagen to suspend trading in NeuroSearch shares from Monday, 14 November at 12.00 CET. The suspension will be lifted when NeuroSearch has released an announcement on the Supreme Court judgment.
Allan Andersen, CEO, telephone: (+45) 4016 3864.
NeuroSearch A/S (NEUR) is listed on NASDAQ Copenhagen A/S.
Last updated on: 14/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.